A Study to Evaluate the Safety and Effectiveness of TT-00420 in Adults with Advanced Cholangiocarcinoma


About this study

The purpose of this trial is to evaluate the effectiveness and safety of TT-00420 in patients with advanced/metastatic and surgically unresectable cholangiocarcinoma (CCA) with 1) FGFR 2 fusions who failed prior FGFR inhibitor treatment, 2) FGFR2 fusions who responded on prior FGFR inhibitor treatment and discontinued due to disease progression, 3) with other FGFR alterations, or 4) whose tumors do not contain a detectable FGFR alteration.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • ≥ 18 years of age, at the time of signing informed consent.
  • Histologically or cytologically documented advanced/metastatic or surgically unresectable cholangiocarcinoma who have received at least one line of prior systemic chemotherapy. Patients will be assigned to 1 of 4 cohorts:
    • Cohort A1: FGFR2 fusions who have failed at least one previous treatment with an FGFR inhibitor;
    • Cohort A2: FGFR2 fusions who have previously responded on at least one previous treatment with an FGFR inhibitor;
    • Cohort B: other FGFR alterations, including FGFR2 mutations and FGFR1/3 alterations, including fusions;
    • Cohort C: negative for FGFR alterations (FGFR wild-type).
  • At least one measurable lesion as defined by RECIST V1.1 criteria for solid tumors.
  • Documentation of FGFR gene alteration status.
  • ECOG performance status of 0 or 1.
  • Adequate organ function confirmed at screening and within 10 days of initiating treatment, as evidenced by:
    • Absolute neutrophil count (ANC) ≥ 1.5 x 10^9 /L;
    • Hemoglobin (Hgb) ≥ 8 g/dl;
    • Platelets (plt) ≥ 75 x 10^9 /L;
    • AST/SGOT and ALT/SGPT ≤ 2.5 x Upper Limit of Normal (ULN) or ≤ 5.0 x ULN if liver metastases are present;
    • Total bilirubin ≤ 1.5 x ULN;
    • Calculated 24-hour clearance ≥ 50 mL/min (Cockcroft Gault formula).
  • Negative pregnancy test within 72 hours before starting study treatment in all premenopausal women and women < 12 months after the onset of menopause.
  • Must agree to take sufficient contraceptive methods to avoid pregnancy (including male and female participants) during the study and until at least 6 months after ceasing study treatment.
  • Able to sign informed consent and comply with the protocol.

Exclusion Criteria:

  • Women who are pregnant or lactating.
  • Women of child-bearing potential (WOCBP) who do not use adequate birth control.
  • Patients with untreated brain or central nervous system (CNS) metastases or brain/CNS metastases that have progressed (e.g. evidence of new or enlarging brain metastasis or new neurological symptoms attributable to brain/CNS metastases) Note: Patients with treated brain metastases that are off corticosteroids and have been clinically stable for 28 days are eligible for enrollment.
  • Patients with a known concurrent malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, carcinoma in situ of the cervix or other noninvasive or indolent malignancy that has previously undergone potentially curative therapy.
  • Patients with the following mood disorders as judged by the Investigator or a psychiatrist:
    • Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia; a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others);
    • ≥ CTCAE grade 3 anxiety.
  • Impaired cardiac function or significant diseases, including but not limited to any of the following:
    • LVEF < 45% as determined by MUGA scan or ECHO;
    • Congenital long QT syndrome;
    • QTcF ≥ 480 msec on screening ECG;
    • Unstable angina pectoris ≤ 3 months prior to starting study drug;
    • Acute myocardial infarction ≤ 3 months prior to starting study drug.
  • Patients with uncontrolled hypertension (defined as blood pressure of ≥ 150 mmHg systolic and/or ≥ 90 mmHg diastolic at Screening).
  • Patients with:
    • unresolved diarrhea ≥ CTCAE grade 2; or
    • impairment of gastrointestinal (GI) function; or
    • GI disease that may significantly alter the absorption of TT-00420.
  • Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g., uncontrolled hypertriglyceridemia [triglycerides > 500 mg/dL], or active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol.
  • Patients who have received chemotherapy, targeted therapy, or immunotherapy ≤ 5 half-lives or 3 weeks, whichever is shorter, (6 weeks for nitrosourea or mitomycin-C) prior to starting study drug.
  • Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered from adverse events of prior therapy.
  • Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from adverse events of prior therapy.
  • Patients who are currently receiving treatment with therapeutic doses of warfarin sodium (Coumadin®) or any other coumarin-derivative anticoagulants.
  • Patients who are currently receiving treatment with strong CYP3A inhibitors or inducers ≤ 2 weeks prior to starting study drug.
  • Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory; patients with well controlled HIV might be enrolled per investigator’s discretion and Sponsor approval).
  • Evidence of active infection with Hepatitis B or Hepatitis C that is not adequately controlled. For patients with known prior history of Hepatitis B or Hepatitis C, enrollment may be allowed per investigator’s discretion and Sponsor approval.
  • Inability to swallow or tolerate oral medication.
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might confound the results of the trial, interfere with the patient’s safe participation and compliance in the trial.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Lionel Aurelien Kankeu Fonkoua, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office


More information


Publications are currently not available

Mayo Clinic Footer